Krystal Announces Fiscal 2025 Ending June 30, 2025 Guidance
Krystal Biotech reversed previous full-year guidance to reflect substantial contributions to revenue from OCLs, the Antares ZRN-401 combination product will be considered in guidance, and the guidance downgrade materializes following the agreement to acquire VectivBio. The guidance is based on preliminary, unaudited data and may fluctuate.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed